Our story

We are committed to building a future together by staying true to our heritage over the past 110 years of adapting, innovating and growing.

1906

Founder Victor Stein extracts sodium alginate from seaweed imported from the North Sea, which he names Norgine.

1920

Norgine launches pharma products and a few years later becomes a supplier of insulin in Europe.

1945

Norgine is re-established in Western Europe.

1960s

Manufacturing starts in our current Dreux and Hengoed sites.

1990

Norgine licenses in and launches KLEAN-PREP®.

1995-2005

Norgine develops and launches MOVICOL® and MOVIPREP®. MOVIPREP® becomes Norgine’s first product approved in the USA.

2013

Norgine launches XIFAXAN® for patients with hepatic encephalopathy.

2015

Norgine in-licenses European rights for LYMPHOSEEK®.

2017

Norgine acquires Merus Labs International Inc. EU approves PLENVU®, the world’s first one litre PEG bowel preparation.

2018

Norgine in-licenses FERACCRU®. FDA approves PLENVU®.

2019

Launch of MOVICOL® in Japan.

2020

Norgine acquires Azanta A/S.

AMAG pharmaceuticals and Norgine B.V. enter into exclusive licensing agreement to commercialize ciraparantag in Europe, Australia and New Zealand.

Dec 2022

GS Asset Management acquires majority control of Norgine.

March 2024

Fennec Pharmaceuticals and Norgine, announce an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI® is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic solid tumors.

Today

Norgine is a leading European specialist pharmaceutical company that has been established for over a century and has a presence in all major European markets, Australia and New Zealand.

Watch our corporate video